Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Palobiofarma SL
Zydus Cadila Joins IO Therapy League With XOMA Tie-up
Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody
Corvus Aims To Master Adenosine Mechanisms For PD-1/L1 Failures
Emerging Company Profile: CEO Richard Miller, who co-founded Idec and Pharmacyclics, explains Corvus's approach of building a pipeline around an emerging target in cancer immunity that may be complementary to checkpoint inhibitors and other therapies.
Venture Funding Deals: $688.8m In Financings From Avitide To Zai Lab
June venture capital financings for emerging companies totaled more than $688.8m, ranging from an undisclosed round for Avitide to a $120m Series B for Rubius Therapeutics.
Novartis Oncology Strategy: Focus On The Microenvironment
As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.